Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Reports 5% Revenue Growth and 10% Adjusted EPS Growth in Q3 2025
Summary
Thermo Fisher Scientific Inc. announced its financial results for the third quarter of 2025, reporting a 5% increase in revenue to $11.12 billion. The company achieved a GAAP diluted EPS of $4.27 and an adjusted EPS of $5.79, reflecting a 10% growth from the same period in the previous year. The earnings release, furnished as Exhibit 99.1, highlighted operational performance, new product launches, strategic collaborations, and acquisitions that contributed to the company's financial success.
Profitelligence Alerts
Get alerts for TMO
Be first to know when Thermo Fisher Scientific Inc. files with the SEC.
Filing Categories
Advertisement
About Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc. is a world-leading biotechnology company that provides essential tools and services for life sciences, biotechnology, pharmaceutical, and healthcare industries. Renowned for its extensive portfolio, the company specializes in offering innovative laboratory products, analytical instruments, and software solutions critical for research, diagnostics, and clinical applications. Thermo Fisher enables scientists to perform complex experiments with cutting-edge technology, from DNA sequencing and cell analysis to clinical diagnostics and specialty chemicals. Serving a vast array of sectors, the company impacts fields such as diagnostics, genetic engineering, and environmental monitoring. Its strategic acquisitions and collaborations strengthen its market presence, making it a go-to partner for scientific advancements and innovation. With operations spanning over 50 countries, Thermo Fisher plays a pivotal role in driving scientific discovery and improving health outcomes globally.
Official SEC Documents
Advertisement